• 1. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 2. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 3. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

2H-Indazole-3-carboxylic acid, 6-iodo-2-methyl (CAS No. 1086386-13-1)

2H-Indazole-3-carboxylic acid, 6-iodo-2-methyl (CAS No. 1086386-13-1) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various biological applications, particularly in the development of novel therapeutic agents.

The indazole core is a well-known heterocyclic structure that is widely used in the design and synthesis of bioactive molecules. The presence of the carboxylic acid group and the iodo substituent at the C-6 position, along with the methyl group at C-2, imparts specific chemical and biological properties to this compound. These functional groups contribute to its solubility, reactivity, and interaction with biological targets, making it an attractive candidate for drug discovery.

Recent studies have highlighted the importance of 2H-Indazole-3-carboxylic acid, 6-iodo-2-methyl in the context of cancer research. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent antiproliferative activity against various cancer cell lines. The mechanism of action involves the inhibition of key enzymes involved in cell cycle progression and apoptosis induction. This finding has sparked interest in exploring its potential as a lead compound for the development of anticancer drugs.

In addition to its anticancer properties, 2H-Indazole-3-carboxylic acid, 6-iodo-2-methyl has also been investigated for its anti-inflammatory effects. Research conducted at a leading pharmaceutical institute revealed that this compound effectively reduces inflammation by modulating the expression of pro-inflammatory cytokines and enzymes. This dual functionality—anticancer and anti-inflammatory—positions it as a valuable candidate for further preclinical and clinical studies.

The synthesis of 2H-Indazole-3-carboxylic acid, 6-iodo-2-methyl typically involves multi-step reactions, starting from readily available starting materials. One common approach involves the condensation of an appropriate aryl hydrazine with a carboxylic acid derivative, followed by iodination and methylation steps. The detailed synthetic route has been well-documented in several research papers, providing a robust foundation for large-scale production and optimization.

From a pharmacological perspective, 2H-Indazole-3-carboxylic acid, 6-iodo-2-methyl has demonstrated favorable pharmacokinetic properties. Studies have shown that it exhibits good oral bioavailability and a reasonable half-life in vivo, which are crucial factors for its therapeutic efficacy. Furthermore, preliminary toxicity assessments indicate that this compound is well-tolerated at therapeutic doses, suggesting a favorable safety profile.

In conclusion, 2H-Indazole-3-carboxylic acid, 6-iodo-2-methyl (CAS No. 1086386-13-1) represents a promising molecule with diverse biological activities. Its unique structural features and favorable pharmacological properties make it an attractive target for further research and development in the pharmaceutical industry. Ongoing studies are expected to uncover additional applications and optimize its potential as a therapeutic agent.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)